<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02894892</url>
  </required_header>
  <id_info>
    <org_study_id>201512127MINC</org_study_id>
    <nct_id>NCT02894892</nct_id>
  </id_info>
  <brief_title>Intragastric pH and Bismuth Effect for H. Pylori Eradication</brief_title>
  <official_title>Intragastric pH and Bismuth Effect for H. Pylori Eradication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Science and Technology, Taipei, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastric cancer is one of the leading causes of cancer-related deaths worldwide. In Taiwan,
      there are around 3800 fresh cases annually, with about 5% of total cancers cases. Gastric
      cancer development is known to follow a multistate process from non-atrophic gastritis,
      atrophic gastritis, intestinal metaplasia, dysplasia, and carcinoma; H. pylori infection
      plays the key role of this carcinogenic process. Although H. pylori eradication would result
      in a marked gastric cancer reduction, treatment success using standard regimens has become
      more difficult in recent years, and increased antibiotic resistance is considered the most
      important reason for decreased treatment efficacy. As no specific new medications have been
      introduced in recent years, novel treatment regimens have been created using different
      combinations, durations and sequences of available medications. The addition of bismuth
      improved the cure rates despite a high prevalence of resistance, and resistance of H. pylori
      to bismuth has not been reported. Bismuth absorption is not required for efficacy in H.
      pylori treatment regimens, suggesting a local mechanism of action. The mechanisms of bismuth
      with responsible for rapid destruction of H. pylori within the stomach remain unclear.
      Knowledge of the mechanism of action of bismuth compounds against H. pylori would be
      beneficial in the development of improved treatment regimens in this era of declining
      eradication success rates. We conduct the pilot study to evaluate the bacteria fragments of
      H. pylori in specimen through electron microscopy after bismuth therapy and provide insight
      into the mechanism of action of pH on bismuth therapy. We also help to develop optimal H.
      pylori therapeutic strategies.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The morphological changes of post-drug H. pylori by electron microscopy.</measure>
    <time_frame>3 years</time_frame>
    <description>Endoscopy: The biopsy procedure protocol specified sampling gastric mucosa in the locations of gastric antrum, body and cardia (two specimens from each location). Specimens would be sent for electron microscopy.
Electron microscopy: Bacteria fragments of H. pylori would be observed.</description>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>(A)Bismuth</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(A)Bismuth (120mg/tab) 1 dose prior 1 hr before endoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(B)Bismuth</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(B)Bismuth (120mg/tab) 1 dose in the morning and endoscopy in the afternoon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(C)Bismuth</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(C)Bismuth (120mg/tab) q.i.d. and endoscopy the next day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(D)Esomeprazole and Bismuth</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(D)3 days esomeprazole (40mg/tab) q.i.d. followed by bismuth (120mg/tab) 1 dose prior 1 hr before endoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(E)Esomeprazole and Bismuth</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(E)3 days esomeprazole (40mg/tab) q.i.d. followed by bismuth (120mg/tab) 1 dose in the morning and endoscopy in the afternoon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(F)Esomeprazole and Bismuth</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(F)3 days esomeprazole (40mg/tab) q.i.d. followed by bismuth (120mg/tab) q.i.d. and endoscopy the next day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(G)Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>(G)These patients underwent endoscopy due to abdominal discomfort or other symptoms and did not have cancers in the digestive tract after series of workup.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(A)Bismuth</intervention_name>
    <arm_group_label>(A)Bismuth</arm_group_label>
    <other_name>(A)Active Comparator-Bismuth</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(B)Bismuth</intervention_name>
    <arm_group_label>(B)Bismuth</arm_group_label>
    <other_name>(B)Active Comparator-Bismuth</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(C)Bismuth</intervention_name>
    <arm_group_label>(C)Bismuth</arm_group_label>
    <other_name>(C)Active Comparator-Bismuth</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(D)Esomeprazole and Bismuth</intervention_name>
    <arm_group_label>(D)Esomeprazole and Bismuth</arm_group_label>
    <other_name>(D)Active Comparator-Esomeprazole and Bismuth</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(E)Esomeprazole and Bismuth</intervention_name>
    <arm_group_label>(E)Esomeprazole and Bismuth</arm_group_label>
    <other_name>(E)Active Comparator-Esomeprazole and Bismuth</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(F)Esomeprazole and Bismuth</intervention_name>
    <arm_group_label>(F)Esomeprazole and Bismuth</arm_group_label>
    <other_name>(F)Active Comparator-Esomeprazole and Bismuth</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>(G)Control</intervention_name>
    <arm_group_label>(G)Control</arm_group_label>
    <other_name>(G)Other-Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Age 20-69

          2. Confirmed H. pylori infection by urea breath test or previous histology

          3. Scheduled endoscopy

          4. Mentally competent to be able to understand the consent form for individuals equal to
             or older than 20

          5. Able to communicate with study staff for individuals equal to or older than 20

          6. Without history of gastric cancer Exclusion criteria

        1.History of gastric cancer

        Deferral criteria:

          1. Having received antibiotic treatment in the previous 15 days

          2. Need of time to decide participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tsung-Hsien Chiang, MD, M.Sc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tsung-Hsien Chiang, MD, M.Sc.</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>65427</phone_ext>
    <email>thchiang@ntu.edu.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tsung-Hsien Chiang, MD, M.Sc.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tsung-Hsien Chiang, MD, M.Sc.</last_name>
      <phone>886-2-23123456</phone>
      <phone_ext>65427</phone_ext>
      <email>thchiang@ntu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2016</study_first_submitted>
  <study_first_submitted_qc>September 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2016</study_first_posted>
  <last_update_submitted>October 12, 2016</last_update_submitted>
  <last_update_submitted_qc>October 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Electron Microscopy</keyword>
  <keyword>Helicobacter pylori</keyword>
  <keyword>Bismuth</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

